$KPTI News

Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis - Slideshow

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026

Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet

Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus

Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Karyopharm Therapeutics Q1 Earnings Call Highlights

Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Posts Q1 Beat and Highlights ASCO Presentation, Shares Surge 7%

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript